The estimated Net Worth of Scott Sukenick is at least $74.9 mil dollars as of 26 April 2022. Mr. Sukenick owns over 3,500 units of Scynexis Inc stock worth over $74,899 and over the last 7 years he sold SCYX stock worth over $0. In addition, he makes $0 as General Counsel at Scynexis Inc.
Scott has made over 3 trades of the Scynexis Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 3,500 units of SCYX stock worth $10,500 on 26 April 2022.
The largest trade he's ever made was buying 3,500 units of Scynexis Inc stock on 26 April 2022 worth over $10,500. On average, Scott trades about 576 units every 108 days since 2017. As of 26 April 2022 he still owns at least 53,499 units of Scynexis Inc stock.
You can see the complete history of Mr. Sukenick stock trades at the bottom of the page.
Scott A. Sukenick, J.D., serves as General Counsel of the Company. Mr. Sukenick joins SCYNEXIS after over a decade addressing a diversity of legal challenges faced by innovative life sciences companies at all stages of development. Mr. Sukenick most recently worked at Cooley LLP, where he focused on life sciences litigation and strategic intellectual property management. Prior to that, he worked at Patterson Belknap Webb & Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation. He started his career at Simpson Thacher & Bartlett LLP, where his practice focused on complex commercial litigation and intellectual property transactional matters. Mr. Sukenick is a registered patent attorney. He obtained a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.
Scott's mailing address filed with the SEC is 101 Hudson St #3610, Jersey City, NJ 07302, USA.
Over the last 11 years, insiders at Scynexis Inc have traded over $4,708,140 worth of Scynexis Inc stock and bought 2,173,590 units worth $13,469,713 . The most active insiders traders include Advisors Llcperceptive Life..., Patrick Machado, eMarco Taglietti. On average, Scynexis Inc executives and independent directors trade stock every 49 days with the average trade being worth of $64,694. The most recent stock trade was executed by Marco Taglietti on 26 April 2022, trading 75,000 units of SCYX stock currently worth $225,000.
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
Scynexis Inc executives and other stock owners filed with the SEC include: